ST Pharm Co.,Ltd.
Financials
Valuation Metrics
ST Pharm Co.,Ltd.'s Market Cap is ₩2.1T. At end of 2025 it was ₩2.5T. Ranked #200 of 2,436 in KR market (top 8%), #38 of 1,649 on KOSDAQ (top 2%), #20 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.10T KRW | KR#200/2,436 Sec#20/234 |
| Revenue | 346.22B KRW | KR#765/2,436 Sec#34/234 |
| Net Income | 69.05B KRW | KR#293/2,436 Sec#21/234 |
| Total Assets | 849.94B KRW | KR#515/2,436 Sec#28/234 |
| Net Assets | 611.25B KRW | KR#420/2,436 Sec#27/234 |
| Employees | 1,328 | KR#196/2,436 Sec#12/234 |
| Value | ||
| P/E | 30.44x | KR#1,256/2,436 Sec#76/234 |
| P/B | 3.44x | KR#2,158/2,436 Sec#173/234 |
| PEG | 0.01x | KR#104/2,436 Sec#3/234 |
| P/S | 6.07x | KR#2,181/2,436 Sec#146/234 |
| EV/EBITDA | 31.53x | KR#1,198/2,436 Sec#79/234 |
| FCF Yield | -1.57% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 11.30% | KR#424/2,436 Sec#28/234 |
| ROA | 8.12% | KR#332/2,436 Sec#25/234 |
| Op. Margin | 18.90% | KR#168/2,436 Sec#18/234 |
| Revenue Growth | 27.74% | KR#513/2,436 Sec#49/234 |
| Earnings Growth | 2044.80% | KR#30/2,436 Sec#2/234 |
| Financial Health | ||
| Debt Ratio | 39.05% | KR#137/2,436 Sec#16/234 |
| Total Debt | 72.02B KRW | KR#838/2,436 Sec#60/234 |
| FCF | -33.08B KRW | KR#2,017/2,436 Sec#195/234 |
| Cash | 111.27B KRW | KR#431/2,436 Sec#21/234 |
| Current Ratio | 2.08x | KR#904/2,436 Sec#104/234 |
| Net Debt/EBITDA | -0.60x | KR#559/2,436 Sec#34/234 |
| Dividend | ||
| Div. Yield | 0.53% | KR#1,273/2,436 Sec#81/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 15.48% | KR#462/2,436 Sec#38/234 |
| 1M Return | -22.84% | KR#2,268/2,436 Sec#224/234 |
| From 52W High | -41.49% | KR#825/2,436 Sec#57/234 |
| 1Y MDD | -49.79% | KR#922/2,436 Sec#76/234 |
| Trading | ||
| Volume | 166,173 shares | KR#671/2,436 Sec#65/234 |
| Foreign Own. | 12.45% | KR#389/2,436 Sec#32/234 |
| Per Share | ||
| EPS | 3,370 KRW | KR#244/2,436 Sec#15/234 |
| BPS | 29,350 KRW | KR#362/2,436 Sec#25/234 |
Company Info
ST Pharm was founded as UCHEM Co., Ltd. in 2008, then changed its name after an absorption merger with Samchully Pharmaceutical in 2010, subsequently joining the Dong-A Socio Group. Leveraging its expertise in small molecule new drugs, the company has expanded into oligonucleotide therapeutics CDMO. ST Pharm holds the world's third-largest production capacity, initiated production with the expansion of its second oligonucleotide plant in 2025, and provides a one-stop service system encompassing new drug development, CRO, and CDMO. It is headquartered in Siheung-si, Gyeonggi-do.